| Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta EM Horwitz, DJ Prockop, LA Fitzpatrick, WWK Koo, PL Gordon, M Neel, ... Nature medicine 5 (3), 309-313, 1999 | 2516 | 1999 |
| A distinct “side population” of cells with high drug efflux capacity in human tumor cells C Hirschmann-Jax, AE Foster, GG Wulf, JG Nuchtern, TW Jax, U Gobel, ... Proceedings of the National Academy of Sciences 101 (39), 14228-14233, 2004 | 1701 | 2004 |
| Inducible apoptosis as a safety switch for adoptive cell therapy A Di Stasi, SK Tey, G Dotti, Y Fujita, A Kennedy-Nasser, C Martinez, ... New England Journal of Medicine 365 (18), 1673-1683, 2011 | 1583 | 2011 |
| Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation CM Rooney, CYC Ng, S Loftin, CA Smith, C Li, RA Krance, MK Brenner, ... The Lancet 345 (8941), 9-13, 1995 | 1366 | 1995 |
| Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus–induced lymphoma in allogeneic transplant recipients CM Rooney, CA Smith, CYC Ng, SK Loftin, JW Sixbey, Y Gan, ... Blood, The Journal of the American Society of Hematology 92 (5), 1549-1555, 1998 | 1357 | 1998 |
| Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma MA Pule, B Savoldo, GD Myers, C Rossig, HV Russell, G Dotti, MH Huls, ... Nature medicine 14 (11), 1264-1270, 2008 | 1343 | 2008 |
| Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma CU Louis, B Savoldo, G Dotti, M Pule, E Yvon, GD Myers, C Rossig, ... Blood, The Journal of the American Society of Hematology 118 (23), 6050-6056, 2011 | 1293 | 2011 |
| CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients B Savoldo, CA Ramos, E Liu, MP Mims, MJ Keating, G Carrum, ... The Journal of clinical investigation 121 (5), 1822-1826, 2011 | 1220 | 2011 |
| Gene-marking to trace origin of relapse after autologous bone-marrow transplantation MK Brenner, DR Rill, RA Krance, JN Ihle, RC Moen, J Mirro, WF Anderson The Lancet 341 (8837), 85-86, 1993 | 1188 | 1993 |
| Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes HE Heslop, CYC Ng, C Li, CA Smith, SK Loftin, RA Krance, MK Brenner, ... Nature medicine 2 (5), 551-555, 1996 | 1019 | 1996 |
| Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma N Ahmed, VS Brawley, M Hegde, C Robertson, A Ghazi, C Gerken, E Liu, ... Journal of clinical oncology 33 (15), 1688, 2015 | 1009 | 2015 |
| Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients HE Heslop, KS Slobod, MA Pule, GA Hale, A Rousseau, CA Smith, ... Blood, The Journal of the American Society of Hematology 115 (5), 925-935, 2010 | 896 | 2010 |
| An inducible caspase 9 safety switch for T-cell therapy KC Straathof, MA Pule, P Yotnda, G Dotti, EF Vanin, MK Brenner, ... Blood 105 (11), 4247-4254, 2005 | 800 | 2005 |
| Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta EM Horwitz, DJ Prockop, PL Gordon, WWK Koo, LA Fitzpatrick, MD Neel, ... Blood, The Journal of the American Society of Hematology 97 (5), 1227-1231, 2001 | 793 | 2001 |
| HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial N Ahmed, V Brawley, M Hegde, K Bielamowicz, M Kalra, D Landi, ... JAMA oncology 3 (8), 1094-1101, 2017 | 699 | 2017 |
| Design and development of therapies using chimeric antigen receptor‐expressing T cells G Dotti, S Gottschalk, B Savoldo, MK Brenner Immunological reviews 257 (1), 107-126, 2014 | 645 | 2014 |
| Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals AM Leen, GD Myers, U Sili, MH Huls, H Weiss, KS Leung, G Carrum, ... Nature medicine 12 (10), 1160-1166, 2006 | 632 | 2006 |
| Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape M Hegde, M Mukherjee, Z Grada, A Pignata, D Landi, SA Navai, ... The Journal of clinical investigation 126 (8), 3036-3052, 2016 | 630 | 2016 |
| Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety V Hoyos, B Savoldo, C Quintarelli, A Mahendravada, M Zhang, J Vera, ... Leukemia 24 (6), 1160-1170, 2010 | 610 | 2010 |
| Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study CRY Cruz, KP Micklethwaite, B Savoldo, CA Ramos, S Lam, S Ku, ... Blood, The Journal of the American Society of Hematology 122 (17), 2965-2973, 2013 | 585 | 2013 |
